title: Multiple myeloma developing during long-term clinical course of refractory immune thrombocytopenic purpura: a case report and review of literature.
abstract: Immune thrombocytopenia (ITP) is an acquired, immune-mediated disease that is characterized by increased destruction of platelets by autoantibodies. Although the onset of the disease and clinical course are highly variable, the disease typically has a benign course. ITP associated with multiple myeloma (MM) has been rarely reported; it is even rarer for MM to develop during a long-term ITP (almost 20 years). Here, we first report on a case with a 20-year long clinical course of refractory ITP followed by newly diagnosed MM.
authors.affiliation: Department of Hematology, Xinqiao Hospital, Third Military Medical University Chongqing, China.
authors.forename: Han
authors.initials: H
authors.lastname: Yao
authors.affiliation: Department of Hematology, Xinqiao Hospital, Third Military Medical University Chongqing, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Hematology, Xinqiao Hospital, Third Military Medical University Chongqing, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Hematology, Xinqiao Hospital, Third Military Medical University Chongqing, China.
authors.forename: Lidan
authors.initials: L
authors.lastname: Zhu
authors.affiliation: Department of Hematology, Xinqiao Hospital, Third Military Medical University Chongqing, China.
authors.forename: Guo
authors.initials: G
authors.lastname: Chen
authors.affiliation: Department of Hematology, Xinqiao Hospital, Third Military Medical University Chongqing, China.
authors.forename: Sha
authors.initials: S
authors.lastname: Wu
authors.affiliation: Department of Hematology, Xinqiao Hospital, Third Military Medical University Chongqing, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Gao
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001707:Biopsy, Needle; D001856:Bone Marrow Examination; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D013997:Time Factors; D016896:Treatment Outcome
keywords: Immune thrombocytopenic purpura; bortezomib; immunosuppression; multiple myeloma
references.citation: Blood. 2005 Dec 1;106(12):3777-84
references.pmid: 16099887
references.citation: Clin Lab Haematol. 2000 Aug;22(4):239-42
references.pmid: 11012639
references.citation: Blood. 2004 Aug 15;104(4):956-60
references.pmid: 15100149
references.citation: Lancet. 1998 Jun 20;351(9119):1833-9
references.pmid: 9652666
references.citation: Oncologist. 2005 Jun-Jul;10(6):412-26
references.pmid: 15967835
references.citation: Blood. 2015 Mar 5;125(10):1541-7
references.pmid: 25575541
references.citation: Blood. 2009 Jun 25;113(26):6511-21
references.pmid: 19395674
references.citation: Int Immunopharmacol. 2012 Jul;13(3):242-4
references.pmid: 22561120
references.citation: CA Cancer J Clin. 2014 Nov-Dec;64(6):422-44
references.pmid: 25266555
references.citation: N Engl J Med. 2005 Jun 16;352(24):2487-98
references.pmid: 15958804